Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CDMONASDAQ:CMRXNASDAQ:ETNBNASDAQ:ITOS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCDMOAvid Bioservices$12.50+0.1%$12.50$6.61▼$12.51$799.18M1.391.41 million shs3.07 million shsCMRXChimerix$8.54$8.54$0.75▼$8.55$801.09M-0.172.66 million shsN/AETNB89BIO$10.00-0.8%$8.62$4.16▼$11.84$1.47B1.31.51 million shs1.26 million shsITOSiTeos Therapeutics$10.11+1.5%$8.40$4.80▼$18.13$381.21M1.51677,151 shs939,806 shs10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCDMOAvid Bioservices0.00%0.00%0.00%0.00%+65.72%CMRXChimerix0.00%0.00%0.00%+0.35%+859.55%ETNB89BIO-0.79%-0.50%+5.37%+24.84%+17.37%ITOSiTeos Therapeutics+1.51%+0.10%+18.11%+55.30%-31.69%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCDMOAvid Bioservices0.6834 of 5 stars1.00.00.04.50.01.70.6CMRXChimerix0.6954 of 5 stars1.00.00.04.10.61.70.6ETNB89BIO2.8557 of 5 stars3.53.00.00.03.80.80.6ITOSiTeos Therapeutics3.3558 of 5 stars4.14.00.00.00.63.30.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCDMOAvid Bioservices 2.00Hold$12.25-1.96% DownsideCMRXChimerix 2.00Hold$8.53-0.08% DownsideETNB89BIO 3.00Buy$26.43164.29% UpsideITOSiTeos Therapeutics 2.14Hold$15.8656.85% UpsideCurrent Analyst Ratings BreakdownLatest ITOS, ETNB, CMRX, and CDMO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/11/2025ETNB89BIOWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (D-) ➝ Sell (D-)5/28/2025ITOSiTeos TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Equal Weight$13.00 ➝ $12.005/28/2025ITOSiTeos TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOutperform ➝ Neutral$10.00 ➝ $12.005/24/2025ETNB89BIOWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (D-) ➝ Sell (D-)5/14/2025ITOSiTeos TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$16.00 ➝ $13.005/14/2025ITOSiTeos TherapeuticsRaymond James FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price Target$12.005/14/2025ITOSiTeos TherapeuticsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$16.00 ➝ $12.005/14/2025ITOSiTeos TherapeuticsLeerink PartnrsSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold5/14/2025ITOSiTeos TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Neutral5/14/2025ITOSiTeos TherapeuticsLeerink PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Market Perform$47.00 ➝ $9.005/13/2025ITOSiTeos TherapeuticsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOverweight ➝ Neutral$15.00 ➝ $8.00(Data available from 6/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCDMOAvid Bioservices$139.91M5.71$0.15 per share80.92$3.02 per share4.14CMRXChimerix$212K3,778.71N/AN/A$2.17 per share3.94ETNB89BION/AN/AN/AN/A$3.34 per shareN/AITOSiTeos Therapeutics$35M11.05N/AN/A$16.16 per share0.63Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCDMOAvid Bioservices-$140.75M-$2.39N/AN/AN/A-101.07%-33.18%-8.45%6/30/2025 (Estimated)CMRXChimerix-$82.10M-$0.99N/AN/AN/AN/A-50.78%-44.94%8/11/2025 (Estimated)ETNB89BIO-$367.08M-$3.38N/AN/AN/AN/A-81.44%-70.17%8/4/2025 (Estimated)ITOSiTeos Therapeutics-$134.41M-$3.04N/AN/AN/AN/A-21.37%-18.55%8/6/2025 (Estimated)Latest ITOS, ETNB, CMRX, and CDMO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/1/2025Q1 2025ETNB89BIO-$0.50-$0.49+$0.01-$0.49N/AN/A4/28/2025Q1 2025ITOSiTeos Therapeutics-$0.94-$0.80+$0.14-$0.80$9.35 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCDMOAvid BioservicesN/AN/AN/AN/AN/ACMRXChimerixN/AN/AN/AN/AN/AETNB89BION/AN/AN/AN/AN/AITOSiTeos TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCDMOAvid Bioservices3.581.300.92CMRXChimerixN/A6.336.33ETNB89BIO0.0618.0318.03ITOSiTeos TherapeuticsN/A14.1314.13Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCDMOAvid Bioservices97.16%CMRXChimerix45.42%ETNB89BION/AITOSiTeos Therapeutics97.16%Insider OwnershipCompanyInsider OwnershipCDMOAvid Bioservices3.05%CMRXChimerix13.10%ETNB89BIO2.60%ITOSiTeos Therapeutics12.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCDMOAvid Bioservices32063.96 million62.01 millionOptionableCMRXChimerix9093.80 million78.15 millionOptionableETNB89BIO40145.98 million141.90 millionOptionableITOSiTeos Therapeutics9038.27 million33.49 millionOptionableITOS, ETNB, CMRX, and CDMO HeadlinesRecent News About These CompaniesiTeos Therapeutics, Inc. (NASDAQ:ITOS) CEO Michel Detheux Sells 43,883 SharesJune 12, 2025 | insidertrades.comiTeos Therapeutics, Inc. (NASDAQ:ITOS) CEO Sells $439,707.66 in StockJune 11, 2025 | marketbeat.comMichel Detheux Sells 43,882 Shares of iTeos Therapeutics, Inc. (NASDAQ:ITOS) StockJune 11, 2025 | marketbeat.comiTeos Therapeutics Inc.June 11, 2025 | barrons.comiTeos Therapeutics validates InvestingPro’s Fair Value analysis with 70% returnJune 9, 2025 | uk.investing.comiTeos Therapeutics, Inc. (NASDAQ:ITOS) Receives Consensus Recommendation of "Hold" from BrokeragesJune 8, 2025 | marketbeat.comInsider Selling: iTeos Therapeutics, Inc. (NASDAQ:ITOS) Director Sells 38,227 Shares of StockJune 7, 2025 | insidertrades.comDavid Hallal Sells 38,227 Shares of iTeos Therapeutics, Inc. (NASDAQ:ITOS) StockJune 6, 2025 | marketbeat.comiTeos Therapeutics, Inc. (NASDAQ:ITOS) Director Sells $391,454.72 in StockJune 6, 2025 | marketbeat.comMichel Detheux Sells 43,883 Shares of iTeos Therapeutics, Inc. (NASDAQ:ITOS) StockJune 6, 2025 | marketbeat.comiTeos Therapeutics, Inc. (NASDAQ:ITOS) CEO Sells $448,035.22 in StockJune 6, 2025 | marketbeat.comStocks With Rising Relative Strength: iTeos TherapeuticsJune 6, 2025 | msn.comNuveen Asset Management LLC Trims Holdings in iTeos Therapeutics, Inc. (NASDAQ:ITOS)June 6, 2025 | marketbeat.comiTeos Therapeutics, Inc. (NASDAQ:ITOS) Shares Bought by Public Employees Retirement System of OhioJune 5, 2025 | marketbeat.comMore bad news in biotech: Watertown cancer firm iTeos shutting downJune 4, 2025 | bostonglobe.comQ2 EPS Forecast for iTeos Therapeutics Decreased by AnalystJune 2, 2025 | marketbeat.comMillennium Management LLC Has $3.16 Million Stock Position in iTeos Therapeutics, Inc. (NASDAQ:ITOS)June 1, 2025 | marketbeat.comiTeos Therapeutics, Inc. (NASDAQ:ITOS) Position Increased by Ameriprise Financial Inc.June 1, 2025 | marketbeat.comWedbush Lowers Earnings Estimates for iTeos TherapeuticsMay 31, 2025 | marketbeat.comiTeos Therapeutics Announces Intent to Wind Down Operations and Explore Asset Sales to Maximize Shareholder ValueMay 30, 2025 | nasdaq.comiTeos Therapeutics (ITOS) Upgraded to Buy: Here's What You Should KnowMay 30, 2025 | zacks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeITOS, ETNB, CMRX, and CDMO Company DescriptionsAvid Bioservices NASDAQ:CDMO$12.50 +0.02 (+0.12%) Closing price 02/5/2025Extended Trading$12.50 0.00 (0.00%) As of 02/5/2025 04:23 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Avid Bioservices, Inc. operates as a contract development and manufacturing organization for the biotechnology and biopharmaceutical industries in the United States. It provides process development and current good manufacturing practice clinical and commercial manufacturing services of biologics, including clinical and commercial drug substance manufacturing, bulk packaging, release and stability testing, regulatory submission and support, upstream and downstream development and optimization, analytical methods development, cell line development, testing, and characterization services. The company was formerly known as Peregrine Pharmaceuticals, Inc. and changed its name to Avid Bioservices, Inc. in January 2018. Avid Bioservices, Inc. was incorporated in 1981 and is based in Tustin, California.Chimerix NASDAQ:CMRX$8.54 0.00 (0.00%) As of 04/21/2025Chimerix, Inc., a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors. The company also develops ONC212, an imipridone agonist of the orphan G protein-coupled receptors (GPCR) tumor suppressor GPR132, as well as ClpP for oncology indications; and CMX521, a nucleoside analog antiviral drug candidate for the treatment of SARS-CoV-2. It has license agreement with SymBio Pharmaceuticals to develop and commercialize TEMBEXA for human diseases other than orthopoxviruses, including smallpox. Chimerix, Inc. was incorporated in 2000 and is headquartered in Durham, North Carolina.89BIO NASDAQ:ETNB$10.00 -0.08 (-0.79%) Closing price 06/23/2025 04:00 PM EasternExtended Trading$10.00 0.00 (0.00%) As of 06/23/2025 06:35 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis; and for the treatment of severe hypertriglyceridemia. The company was incorporated in 2018 and is headquartered in San Francisco, California.iTeos Therapeutics NASDAQ:ITOS$10.11 +0.15 (+1.51%) Closing price 06/23/2025 04:00 PM EasternExtended Trading$10.06 -0.04 (-0.45%) As of 06/23/2025 05:13 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.iTeos Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Microsoft Stock Holds Steady as AI Drives Workforce Shift Top International ETFs With Dividends and Market-Beating Returns D-Wave Goes International With South Korea Partnership BigBear.ai Poised to Benefit as Palantir Dominates AI Defense Kroger Stock Confirms Buy Signal as Uptrend Gains Strength Darden Stock Set to Sizzle After Blowout Q4 and $1B Buyback Alphabet’s Comeback: The Hidden Engines Powering Google New All-Time Highs Coming for Broadcom? Wall Street Says Yes Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
